同步放化疗治疗局部晚期喉癌的适应证探讨  

Study on the indication of concurrent chemoradiotherapy for locally advanced laryngeal carcinoma

作　　者：王文静 皇甫辉[2] 侯彦杰[3] 冯彦[2] 张春明[2] 翟宋玉 李梦璐 WANG Wenjing;HUANGFU Hui;HOU Yanjie;FENG Yan;ZHANG Chunming;ZHAI Songyu;LI Menglu(First Clinical Medical College of Shanxi Medical University,Taiyuan,030000,China;Department of Otorhinolaryngology Head and Neck Surgery,First Hospital of Shanxi Medical University;Department of Radiotherapy,First Hospital of Shanxi Medical University)

机构地区：[1]山西医科大学第一临床医学院,太原030000 [2]山西医科大学第一医院耳鼻咽喉头颈外科 [3]山西医科大学第一医院放疗科

出　　处：《临床耳鼻咽喉头颈外科杂志》2022年第9期721-725,共5页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

摘　　要：喉癌是头颈部常见的恶性肿瘤之一,美国国立综合癌症网络(NCCN)临床实践指南认为同步放化疗是局部晚期喉癌最有效的器官保护策略,可在不降低患者生存率的前提下保留患者喉部。非T4(T1~3)、高淋巴结负担(N2~3)的喉癌患者可以从同步放化疗中受益,相较于其他分期的局部晚期喉癌更适合接受同步放化疗。本文就同步放化疗的适应证进行探讨。Laryngeal cancer is one of the most common malignant cancer of the head and neck.Concurrent chemoradiotherapy is considered by the NCCN guideline to be the most effective organ protection strategy for locally advanced laryngeal cancer,which can preserve the larynx without reducing the survival rate of patients.Patients with non-T4(T1-3)and high lymph node burden(N2-3)laryngeal cancer can benefit from concurrent chemoradiotherapy,which are more suitable for concurrent chemoradiotherapy than locally advanced laryngeal cancer with other stages.The indications of concurrent chemoradiotherapy were further discussed in this paper.

关 键 词：喉肿瘤 放射疗法 化学疗法 适应证 

分 类 号：R739.65[医药卫生—肿瘤]